# GPRC5D expression

Source: https://onco.cc/biomarkers/gprc5d-expression/  
OnCo record `gprc5d-expression` (Biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GPRC5D is a receptor on myeloma cells and in hair follicles, nails and taste buds. Talquetamab targets it without any test, and the side effects on skin, nails and taste follow from where it is expressed.

## Summary

Talquetamab (Talvey) is a GPRC5D x CD3 bispecific labelled for relapsed or refractory multiple myeloma after at least four prior lines; the label names GPRC5D only as the target. Expression on plasma cells is high and independent of BCMA, which is why GPRC5D-directed therapy works after BCMA failure; GPRC5D loss at relapse has been described.

## Fields

- Kind: Biomarker
- Last checked: 2026-09-23
- Also known as: GPRC5D; GPRC5D-positive; GPRC5D expression myeloma
- Tags: biomarker; surface-antigen; no-threshold

## Sources

- TALVEY prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9001355e-003d-4d4e-b4ce-337e0fd14952

## Connected records

- biomarkers: [BCMA expression](https://onco.cc/biomarkers/bcma-expression/), [CD38 expression](https://onco.cc/biomarkers/cd38-expression/), [FcRH5 expression](https://onco.cc/biomarkers/fcrh5-expression/)
- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [Talquetamab](https://onco.cc/drugs/talquetamab/)
- terms: [Antigen escape (antigen loss, lineage switch)](https://onco.cc/terms/antigen-escape/)
- targets: [GPRC5D](https://onco.cc/targets/gprc5d/)

---
JSON: https://onco.cc/api/v1/entities/gprc5d-expression.json